Zhou Youlian, Chen Ye
Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. E-mail:
Nan Fang Yi Ke Da Xue Xue Bao. 2013 Dec;33(12):1833-8.
Infliximab has shown its superiority and safety in the treatment of inflammatory bowel disease (IBD) that failed to respond to traditional medical therapy, in refractory cases with obvious adverse reactions, and in "top-down therapy". For standardized and effective management of IBD, experts worldwide have consecutively issued the 2010 European ECCO guide, 2011 London consensus, and 2012 Chinese consensus. In this paper, based on the latest expert consensus worldwide, we reviewed the efficacy of infliximab treatment on IBD and the factors affecting its therapeutic effect.
英夫利昔单抗已在对传统药物治疗无反应的炎症性肠病(IBD)、有明显不良反应的难治性病例以及“自上而下治疗”中显示出其优越性和安全性。为了对IBD进行标准化和有效的管理,全球专家相继发布了2010年欧洲ECCO指南、2011年伦敦共识和2012年中国共识。在本文中,我们基于全球最新的专家共识,综述了英夫利昔单抗治疗IBD的疗效及其影响治疗效果的因素。